IceCure Medical (NASDAQ: ICCM) shareholders back all agenda items at meeting

Rhea-AI Filing Summary

IceCure Medical Ltd. convened its Annual and Special General Meeting of Shareholders on August 20, 2025. A quorum was present, and shareholders approved all agenda items that had been described in the company’s proxy statement furnished to the SEC on July 16, 2025. The report notes that this information is incorporated by reference into IceCure Medical’s existing registration statements on Form F-3 and Form S-8, meaning those registration statements now include the outcomes of this meeting as part of their disclosure record.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025 (Report No. 3)

Commission file number: 001-40753

ICECURE MEDICAL LTD.

(Translation of registrant’s name into English)

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F        ☐ Form 40-F

CONTENTS

On August 20, 2025, IceCure Medical Ltd. (the “Company”) convened its Annual and Special General Meeting of Shareholders (the “Meeting”).

At the Meeting, a quorum was present and the shareholders of the Company voted upon and approved, by the applicable required majority, all agenda items that were described in the Company’s proxy statement for the Meeting, which were included in Exhibit 99.2 to the Company’s Report of Foreign Private Issuer on Form 6-K that the Company furnished to the Securities and Exchange Commission (“SEC”) on July 16, 2025 (the “Proxy Statement”).

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (Registration Nos. 333-267272 and 333-258660) and Form S-8 (Registration Nos. 333-270982, 333-264578, 333-262620, and 333-281587), filed with the SEC, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IceCure Medical Ltd.
Date: August 20, 2025	By:	/s/ Eyal Shamir
		Name:	Eyal Shamir
		Title:	Chief Executive Officer

2

FAQ

What did IceCure Medical (ICCM) report in this August 2025 Form 6-K?

IceCure Medical reported that it held its Annual and Special General Meeting of Shareholders on August 20, 2025, and that shareholders approved all agenda items described in its earlier proxy statement.

Were all proposals approved at IceCure Medical’s August 20, 2025 shareholder meeting?

Yes. The company states that a quorum was present and that shareholders approved all agenda items at the Meeting by the applicable required majority.

How is this IceCure Medical (ICCM) 6-K related to its proxy statement?

The company explains that the items approved at the Meeting were those described in its proxy statement furnished to the SEC on July 16, 2025, which outlined the agenda for the Annual and Special General Meeting.

Does this IceCure Medical Form 6-K affect its existing registration statements?

Yes. The report states that it is incorporated by reference into IceCure Medical’s registration statements on Form F-3 and Form S-8, so those filings now include this meeting information.

Which registration statements does IceCure Medical incorporate this 6-K into?

The report is incorporated by reference into IceCure Medical’s Form F-3 registration statements (Registration Nos. 333-267272 and 333-258660) and Form S-8 registration statements (Registration Nos. 333-270982, 333-264578, 333-262620, and 333-281587).

Who signed the August 20, 2025 IceCure Medical Form 6-K?

The Form 6-K was signed on behalf of IceCure Medical Ltd. by Eyal Shamir, who is identified as the company’s Chief Executive Officer, dated August 20, 2025.